Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional disruptions of the brain network in low back pain: a graph-theoretical study.

Neuroradiology·2023
Same author

Probiotics for preventing acute upper respiratory tract infections.

The Cochrane database of systematic reviews·2022
Same author

Thrombolytic therapy for pulmonary embolism.

The Cochrane database of systematic reviews·2021
Same author

Potassium channel Shaker play a protective role against cardiac aging in Drosophila.

Yi chuan = Hereditas·2021
Same author

Thrombolytic therapy for pulmonary embolism.

The Cochrane database of systematic reviews·2018
Same author

Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease.

Journal of digestive diseases·2018

Related Experiment Video

Updated: May 13, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Macrolides for diffuse panbronchiolitis.

Ming Yang1, Bi Rong Dong, Jing Lu

  • 1Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. yangmier@gmail.com

The Cochrane Database of Systematic Reviews
|March 2, 2013
PubMed
Summary
This summary is machine-generated.

Limited evidence supports macrolide antibiotics for diffuse panbronchiolitis (DPB). A single trial showed improvements in CT scans with erythromycin, but more research is needed to confirm macrolide efficacy for DPB.

Related Experiment Videos

Last Updated: May 13, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Diffuse panbronchiolitis (DPB) is a chronic airway disease prevalent in East Asian populations.
  • Macrolides are commonly prescribed for DPB, yet evidence primarily stems from non-randomized studies.
  • The efficacy and safety of macrolides for DPB require rigorous evaluation.

Purpose of the Study:

  • To systematically assess the efficacy and safety of macrolide antibiotics in treating diffuse panbronchiolitis (DPB).
  • To synthesize evidence from randomized controlled trials (RCTs) and quasi-RCTs.

Main Methods:

  • Searched multiple databases including MEDLINE, EMBASE, CENTRAL, CBM, CNKI, KoreaMed, and Japana Centra Revuo Medicina up to July 2012.
  • Included randomized controlled trials (RCTs) or quasi-RCTs evaluating macrolides for DPB.
  • Assessed study quality and risk of bias; analyzed outcomes like five-year survival, lung function, and clinical response using risk ratios and 95% confidence intervals.

Main Results:

  • Only one RCT with 19 participants and methodological limitations was identified.
  • All participants receiving long-term, low-dose erythromycin showed improved CT scan images.
  • Control group participants experienced worsening or unchanged CT scan images; adverse effects were not reported.

Conclusions:

  • Current evidence supporting macrolide use for DPB is minimal.
  • The review cannot provide new treatment recommendations for DPB.
  • Existing guidelines suggest low-dose macrolides for at least six months post-diagnosis may be reasonable.